Diabetes-Specific Oral Nutritional Supplement for Prediabetes Improves Postprandial Glycemic Response

If you formulate oral nutritional supplements, post-meal glucose control is one of the hardest targets to hit. A standard product has to deliver calories, protein, and carbs. Those carbs can spike blood sugar. New research shows a diabetes-specific formula with allulose can change that picture.

The trial compared a diabetes-specific oral nutritional supplement (DSNF) with a standard oral nutritional supplement (ONS). Both were tested in people with prediabetes. The DSNF was not a magic formula. It simply did something smart: it included allulose and lowered available carbohydrates.

Background

Prediabetes means blood glucose runs higher than normal, but not high enough for a type 2 diabetes diagnosis. Postprandial spikes matter at this stage. They stress the insulin system and can push someone toward diabetes.

Oral nutritional supplements are common in hospitals, care facilities, and even retail meal replacement products. Many contain maltodextrin, sucrose, or other fast-acting carbs. That creates a problem for people who need nutrition support but cannot afford a glucose spike. A formula designed for diabetes should blunt that response.

What the study did

The researchers gave one group a DSNF and compared it to a standard ONS. Each 200 mL serving of the DSNF contained 3 g of allulose. The standard ONS had 0 g. The DSNF also had lower available carbohydrates overall.

The key outcome was postprandial glucose response, measured as incremental area under the curve, or iAUC. This number captures the full post-meal glucose excursion, not just one fingerstick.

Key findings

The difference was impossible to miss. The DSNF produced a glucose iAUC of 1,683.49. The standard ONS produced 4,455.92. That difference was statistically significant with a P value below 0.0001.

The authors tied the result to allulose and to the formula’s lower available carbohydrate load. They also highlighted three mechanisms for allulose. It inhibits glucose absorption in the gut. It stimulates GLP-1 release. And it promotes glycogen storage in the liver.

Each mechanism matters for a different reason. Blocking glucose absorption reduces the initial flood. GLP-1 helps regulate insulin and satiety signals. Liver glycogen storage pulls glucose out of circulation. Together, they make a post-meal curve flatter and lower.

Parameter	DSNF (allulose formula)	Standard ONS
Allulose per 200 mL	3 g	0 g
Available carbohydrate	Lower	Higher
Postprandial glucose iAUC	1,683.49	4,455.92
P value	< 0.0001	—

What it means for manufacturers

This is not just a clinical curiosity. It gives you a formulation blueprint.

First, allulose needs to be present at a real dose. 3 g per serving moved glucose response in this study. That is a practical number. You can hit it without making a product taste odd. Allulose also contributes sweetness, so formulators can reduce added sugar while keeping palatability.

Second, allulose alone is not the whole answer. The DSNF also had lower available carbohydrate. If you simply add allulose to a high-carb formula, you may not get the same result. The total glucose burden still matters. The winning approach is to lower the carbs and use allulose to flatten the curve further.

Third, think about GLP-1. Food and beverage buyers increasingly look for products that support incretin pathways. Allulose’s effect on GLP-1 makes it more than just a low-calorie sweetener. You can position it as a functional ingredient in medical nutrition, diabetes care, and even mainstream metabolic health products.

FAQ

Does this mean allulose is proven to prevent diabetes?
No. The study measured postprandial glucose response, not diabetes progression. It shows promise for managing glucose spikes, not for preventing the disease over time.

Can I apply this to a type 2 diabetes product?
The study looked at prediabetes. The mechanisms are relevant to type 2 diabetes, but you should not claim equivalence without clinical work in that specific population.

Why did the DSNF outperform the standard ONS?
Two reasons appeared in the product design. The DSNF contained 3 g of allulose per 200 mL, and it had lower available carbohydrate than the standard ONS. Both factors contributed to the lower glucose iAUC.

The practical picture

This paper gives formulators something they can use. It reports a clean comparison, a significant outcome, and a specific allulose level. It also shows that a commercial-style product, not just an isolated ingredient, can deliver meaningful glucose benefits.

If you are developing a diabetes-specific ONS, this is a strong reference point. Start with a moderate allulose dose. Cut available carbs. Measure the postprandial response in your own product. The formula behind these numbers sets a clear benchmark for what is possible. What matters now is turning that evidence into products people will actually drink.